Out to ‘re­think the drug de­sign process,’ AI star Daphne Koller is cre­at­ing a new ma­chine learn­ing ven­ture at in­sitro with some heavy­weight back­ers

Daphne Koller has been busy.

Just two months since the high pro­file AI ex­pert ex­it­ed Google’s an­ti-ag­ing biotech Cal­i­co Labs, where she was chief com­put­ing of­fi­cer, Koller has gath­ered a group of mar­quee in­vestors to back a tech up­start — in­sitro — with plans to de­vel­op a ma­chine learn­ing plat­form equipped with cus­tom-built datasets to cre­ate a new and far more ef­fi­cient ap­proach to drug dis­cov­ery and de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER